Stockwinners Market Radar for September 13, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:50 EDT Knightscope Inc trading halted, news pending

17:33 EDT Tivic Health names Lisa Wolf as Interim CFO - Tivic Health is pleased to announce the appointment of Lisa Wolf as Interim CFO of the company, effective October 1, 2024. Wolf will take over from Kimberly Bambach, who has served as the company's interim CFO since April 2023. Bambach will continue with Tivic in an advisory role for strategic transactions and other special projects. Wolf brings 30 years of financial leadership experience in public and private companies, spanning multiple industries. She has built a deep understanding of Tivic's financial landscape during her tenure serving the company and has a history of significant contributions, including streamlining the company's financial operations. Wolf also currently serves as Vice President of Murdock Martell and has previously held positions at Resonant, Inc. and Arthur Andersen.

17:17 EDT General Dynamics receives $780M block-buy Navy contract - General Dynamics announced that it has received a block-buy contract from the U.S. Navy for the construction of up to eight additional John Lewis-class fleet replenishment oilers. The tenth ship, and first under the new contract, has been awarded for $780M. If all eight ships are ultimately exercised, and including incentives and other contract options in support of those ships, the contract value will total over $6.7B.

17:05 EDT Caesars announces first in-person sports wagering location in Maine - Caesars Entertainment celebrated the first in-person sports wagering location in the state of Maine at the newly opened sports entertainment venue, Oddfellahs, powered by Caesars Sportsbook. Made possible through Caesars Sportsbook's partnership with First Tracks Investments LLC, the new state-of-the-art sports bar brings in-person sports betting to the Pine Tree State for the first time. Oddfellahs commemorated its grand opening in the heart of downtown Portland at 55 Market St. with a ceremonial first bet placed by Portland Mayor Mark Dion alongside representatives from Caesars Sportsbook, First Tracks, the Portland City Council, and the Maine Gambling Control Unit.

16:09 EDT Eli Lilly announces FDA approval of EBGLYSS - Eli Lilly and Company announced the U.S. FDA approved EBGLYSS, a targeted IL-13 inhibitor, for the treatment of adults and children 12 years of age and older who weigh at least 88 pounds with moderate-to-severe atopic dermatitis that is not well controlled despite treatment with topical prescription therapies. Eczema inflammation under the skin can lead to symptoms seen and felt on the outside. EBGLYSS works by targeting eczema inflammation throughout the body that can lead to dry, itchy and irritated skin.

16:04 EDT KKR to purchase 11.62M shares of BrightSpring Health from Walgreens - BrightSpring Health (BTSG) announced that investment funds managed by KKR, an existing shareholder of BrightSpring, have entered into an agreement with Walgreens (WBA) to purchase 11,619,998 shares of BrightSpring's common stock from WBA in a private transaction. The transaction was negotiated directly between KKR and WBA, with KKR making the investment through its private equity funds. BrightSpring is not issuing or selling any shares of common stock in connection with the transaction, which is expected to close on or about September 16.

15:37 EDT ACRI Capital Acquisition Corp trading resumes

14:58 EDT Walgreens pays $106.8M to resolve False Claims Act allegations - Walgreens Boots Alliance has agreed to pay $106.8M to resolve alleged violations of the False Claims Act and state statutes for billing government health care programs for prescriptions never dispensed, the Department Justice said in a statement. The government alleges that, between 2009 and 2020, Walgreens submitted false claims for payment to Medicare, Medicaid and other federal health care programs for prescriptions that it processed but that were never picked up by beneficiaries. As part of the resolution, Walgreens received credit under the department's guidelines for taking disclosure, cooperation and remediation into account in False Claims Act cases. Among other actions, Walgreens implemented enhancements to its electronic pharmacy management system to prevent this from occurring in the future and self-reported certain conduct. Reference Link

14:31 EDT Trump Media trading resumes

13:54 EDT JBDI Holdings Ltd trading resumes

13:36 EDT BuzzFeed jumps 16% to $2.90 after Bloomberg 'Hot Ones' report

13:31 EDT FDA approves Genentech's Ocrevus Zunovo - Genentech, a member of the Roche Group, announced that the United States Food and Drug Administration has approved Ocrevus Zunovo for the treatment of relapsing multiple sclerosis and primary progressive multiple sclerosis. "Ocrevus Zunovo is the first and only twice-a-year, healthcare professional (HCP)-administered approximately 10-minute subcutaneous injection approved for both these forms of multiple sclerosis, giving people living with MS more treatment options," the company stated. "Ocrevus Zunovo gives patients and providers another option for receiving Ocrevus, building on a decade of robust safety and efficacy data for Ocrevus in multiple sclerosis. Today's approval may offer greater flexibility for healthcare providers and people living with multiple sclerosis, based on their individual treatment needs," said Levi Garraway, M.D., Ph.D., Genentech's chief medical officer and head of Global Product Development.

13:02 EDT Baker Hughes reports U.S. rig count up 8 to 590 rigs - Baker Hughes reports that the U.S. rig count is up 8 from last week to 590 with oil rigs up 5 to 488, gas rigs up 3 to 97 and miscellaneous rigs unchanged at 5. The U.S. Rig Count is down 51 rigs from last year's count of 641 with oil rigs down 27, gas rigs down 24 and miscellaneous rigs unchanged. The U.S. Offshore Rig Count is up 2 to 21, up 2 year-over-year. The Canada Rig Count is down 2 from last week to 218, with oil rigs down 2 at 150, gas rigs unchanged to 67 and miscellaneous rigs unchanged at 1. The Canada Rig Count is up 28 from last year's count of 190, with oil rigs up 31, gas rigs down 4 and miscellaneous rigs up 1.

12:35 EDT Moody's places Boeing on review for downgrade after worker strike - Moody's placed all of Boeing ratings on review for downgrade, including the Baa3 senior unsecured rating and P-3 commercial paper rating. "This follows this morning's strike by the company's aircraft mechanics and assemblers represented by The International Association of Machinists District 751. About 95% of the union membership voted to reject the tentative agreement and to strike. Aircraft production across the company's Seattle, Washington area factories will cease until the parties agree to contract terms that the membership will ratify," the agency said in a statement. It believes a prolonged strike "would fracture the recovery of the Commercial Airplanes business, which remains in its early stages."

12:18 EDT Azul jumps 24% to $2.60 after Reuters report of new debt deal

12:11 EDT Boeing to take 'necessary actions' to keep investment rating, says CFO

12:08 EDT Boeing CFO: 'Strike injects so much uncertainty'

12:03 EDT Boeing CFO: LT fundamentals haven't changed, but have moved to the right

12:00 EDT Similarweb falls -12.1% - Similarweb is down -12.1%, or -$1.16 to $8.41.

12:00 EDT Wolfspeed rises 13.8% - Wolfspeed is up 13.8%, or $1.11 to $9.16.

12:00 EDT RH rises 24.8% - RH is up 24.8%, or $63.63 to $320.12.

11:58 EDT Mullen Automotive announces reverse stock split, effective September 17 - Mullen Automotive announced that it will effect a 1-for-100 reverse stock split of its common stock, par value $0.001 per share, that will become effective on September 17, at 12:01 a.m. Eastern Time. The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol MULN and will begin trading on a split-adjusted basis when the market opens on September 17. The Reverse Stock Split is primarily intended to bring the company into compliance with the $1.00 minimum bid price requirement for maintaining its listing on Nasdaq. There is no guarantee the company will meet the minimum bid price requirement.

11:55 EDT Boeing: 'Things were starting to move in right direction' before work stoppage

11:16 EDT Telesat announced completion of C$2.54B funding agreements with Canada, Quebec - Telesat announced the completion of funding agreements with the Government of Canada and the Government of Quebec for its highly advanced Telesat Lightspeed Low Earth Orbit, or LEO, broadband satellite constellation. "With this milestone completed, Telesat now has all financing sources in place to fund the global Telesat Lightspeed network, including the satellites, launch vehicles to deploy them, an integrated terrestrial network of landing stations and points of presence throughout the world, and the business and operational support systems for the network. All amounts are in Canadian dollars unless otherwise noted. As previously disclosed, the Government of Canada loan is for $2.14 billion and will carry a floating interest rate that is 4.75% above the Canadian Overnight Repo Rate Average - CORRA - with a 15-year maturity. Interest is payable in-kind during the Telesat Lightspeed construction period, followed by a 10-year sculpted amortization. Furthermore, the Government of Canada is receiving warrants for 10% of the common shares of Telesat LEO based upon an equity valuation for Telesat LEO of US$3 billion. The Government of Quebec loan is for $400 million and has terms that largely mirror the Government of Canada loan but with warrants for 1.87%, in proportion to the smaller loan amount. The borrower under each loan, Telesat LEO, is a subsidiary of Telesat," the company stated.

10:53 EDT Marshall & Ilsley Corporation trading halted, volatility trading pause

10:23 EDT ViaSat slides after United Airlines inks Starlink deal with SpaceX - Shares of Viasat (VSAT), a provider of high-speed satellite broadband services and secure networking systems, are lower in early trading after United Airlines (UAL) announced it has "set a new standard of inflight connectivity by signing the industry's largest agreement of its kind with SpaceX to bring Starlink's fast, reliable Wi-Fi service to the airline's mainline and regional aircraft fleet, for free." United is "the largest airline across both the Atlantic and Pacific and will be the first carrier in the world to commit to offering Starlink service at this scale," according to the airline, which noted that testing begins in early 2025 with the first passenger flights expected later that year. William Blair analyst Louie DiPalma has said that Viasat will still be the aviation market share leader five years from now given the slow-moving nature of the industry, but adds that Starlink is "positioned to have the highest aviation market share over the next decade as this landmark deal will likely lead to other wins." Following the news, shares of Viasat are down $2.02, or 13.5%, to $13.00, while Gogo (GOGO), another player in the aviation broadband market, are off pre-market lows to be down 2% to $7.30.

10:08 EDT Jet.AI opens JetLeg.AI app to beta testers - Jet.AI invites users to beta test the web version of JetLeg.AI, designed as an iOS/Android app that redirects previously wasted empty private flights into new lower cost charters. The easy-to-use app features AI trip finding, matching, and suggestions. Users may sign up and explore JetLeg.AI's capabilities in advance of live connectivity to the aircraft operator community. Available on the Web, with native iOS and Android apps coming this fourth quarter, the app is powered by Jet.AI's Reroute AI technology, delivering an intuitive and personalized travel experience.

10:05 EDT Instill Bio trading resumes

10:04 EDT Prelude Therapeutics reports results from Phase 1 trial of PRT3789 - Prelude Therapeutics announced the first interim clinical data from its ongoing Phase 1 open-label, dose-escalation trial of PRT3789, a first-in-class SMARCA2 degrader, highly selective for SMARCA2 and designed to treat cancer patients with a SMARCA4 mutation. The data were presented at the European Society for Medical Oncology Congress 2024 in Barcelona, Spain. The study investigators reported that, as of the August 5, 2024 data cutoff date, 65 patients were safety evaluable, enrolled and treated. This included 46 efficacy evaluable patients with any tumor type harboring any SMARCA4 mutation. As reported by the study investigators, PRT3789 was generally well-tolerated through 8 dosing cohorts. Dose escalation continues, now in the 9th dosing cohort. The majority of adverse events reported by investigators have been mild to moderate. A maximum tolerated dose has not yet been identified. Overall, of the 26 advanced, heavily pre-treated NSCLC or esophageal patients evaluable for efficacy, 7 had tumor shrinkage. RECIST confirmed partial responses were observed in 3 patients. Additional patients demonstrated clinical benefit as measured by prolonged stable disease including one patient on treatment for more than 1 year.

10:00 EDT Instill Bio trading halted, volatility trading pause

10:00 EDT Nuscale Power rises 9.5% - Nuscale Power is up 9.5%, or 82c to $9.45.

10:00 EDT Garmin falls -6.0% - Garmin is down -6.0%, or -$10.96 to $171.05.

10:00 EDT Similarweb falls -14.4% - Similarweb is down -14.4%, or -$1.38 to $8.19.

09:48 EDT Garmin falls -4.9% - Garmin is down -4.9%, or -$8.99 to $173.02.

09:48 EDT Similarweb falls -12.2% - Similarweb is down -12.2%, or -$1.17 to $8.40.

09:47 EDT Wayfair rises 7.1% - Wayfair is up 7.1%, or $3.17 to $47.95.

09:45 EDT Garden Stage Ltd trading resumes

09:39 EDT Oblong trading resumes

09:35 EDT Garden Stage Ltd trading halted, volatility trading pause

09:33 EDT Nova Vision Acquisition Corp trading halted, volatility trading pause

09:28 EDT Novavax 2024-2025 formula COVID-19 vaccine available at major U.S. pharmacies - Novavax announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) (NVX-CoV2705) to prevent COVID-19 in individuals aged 12 and older are in stock at major pharmacy retailers across the U.S. Through agreements with pharmacies, Novavax's updated vaccine is expected to be widely available in locations including, but not limited to, CVS Pharmacy, Rite Aid, Walgreens, Costco, Publix, Sam's Club, Kroger, Meijer, hundreds of other regional grocers and thousands of independent pharmacies. Novavax's updated vaccine received Emergency Use Authorization on August 30, 2024 from the U.S. FDA.

09:07 EDT Sealsq announces its adoption of the RISC-V architecture - SEALSQ announced that its adoption of the RISC-V architecture will come to fruition with the release of the engineering samples of its first Quantum Resistant chips in late 2024. This achievement reflects SEALSQ's forward-thinking strategy, aligning with the rising global demand for Edge-AI and machine learning applications which will contribute to grow RISC V products market share up to 25% by 2030 according to research by Omdia. As a result, the Company is driving a significant paradigm shift in the microchip industry. This shift is not just about the technology itself but also about how semiconductors are designed and utilized to meet emerging needs, particularly in decentralized computing and sustainable practices.

09:05 EDT Agape ATP partners with Photons Solar to advance solar PV mounting systems - AGAPE ATP Corporation, through its subsidiary, ATPC Green Energy, has entered into a strategic collaboration with Xiamen Photons Solar Technology, a value chain partner of a Shenzhen Stock Exchange-listed Fujian Minfa Aluminium. This collaboration focuses on developing solar photovoltaic mounting systems for Malaysia and ASEAN countries. The agreement was signed at Photons Solar's headquarters in Xiamen, China.

09:03 EDT Alpha Star Acquisition enters business combination agreement with XDATA - Alpha Star Acquisition announced the execution of a business combination agreement on September 12, 2024,, pursuant to which Alpha Star will undergo a business combination with OU XDATA GROUP, an Estonia-based financial technology solutions company. The transaction has been approved by the boards of directors of Alpha Star and XDATA and is expected to be consummated in late 2024. The closing of the transaction is subject to regulatory approval, approval by the shareholders of Alpha Star and XDATA and the satisfaction of certain other customary closing conditions. The Business Combination Agreement provides for SPAC will incorporate a Cayman Islands exempted company in accordance with the Companies Act of the Cayman Islands, the merger of Alpha Star with and into PubCo, with PubCo surviving the Reincorporation Merger, and (iii) the share exchange between PubCo and the shareholders of XDATA, resulting in XDATA being a wholly owned subsidiary of PubCo. Following the closing of the Proposed Transaction, XDATA will operate through PubCo, and PubCo will be a publicly traded company listed on the Nasdaq Stock Market. The board of directors of both XDATA and ALSA have unanimously approved the Proposed Transaction, which is expected to be completed later this year, subject to, among other things, the approval of the shareholders of XDATA and ALSA and other customary closing conditions, including but not limited to a registration statement on Form F-4 to be filed by PubCo being declared effective by the SEC, and the listing application of XDATA being approved by the Nasdaq Stock Market LLC.

09:01 EDT Top KingWin's Guji Technology orders servers to provide hardware support - Top Kingwin announced its subsidiary, Guji Technology, has ordered 1,300 units of Lenovo ThinkSystem servers from companies including Qingchao Industrial. These servers will provide Guji Technology's clients with hardware support, aimed at building a technological infrastructure and promoting the application of intelligent solutions. Company CEO stated, "The hardware infrastructure for our AI business is critical. By purchasing these servers, we aim to provide our clients with a powerful hardware platform to support their various needs in AI projects. We believe that high-quality hardware is the first step in helping our clients achieve their AI strategic goals."

08:55 EDT Rezolve AI, Creative Dock partner to drive digital innovation in commerce - Rezolve AI announces a strategic partnership with Creative Dock, a global leader in corporate venture building and digital innovation. This collaboration aims to revolutionize the commerce sector by combining Rezolve AI's cutting-edge technology with Creative Dock's expertise in building innovative ventures that drive value for businesses. "As pioneers in AI for commerce, we are thrilled to join forces with Creative Dock to redefine how businesses engage with their customers," said Daniel M Wagner, CEO and Chairman of Rezolve AI. "Together, we will empower companies to fuel growth, unlock new digital opportunities, and elevate the customer experience."

08:49 EDT Acreage Holdings enters amended, restated credit agreement - Acreage Holdings (ACRHF) announce that it has entered into an amended and restated credit agreement with a subsidiary of Canopy Growth Corporation (CGC) and a third-party lender, amending the amended and restated credit agreement dated June 3, 2024 among Acreage, High Street Capital Partners as borrower, and the other parties thereto. The New Lender advanced $65M with an original issue discount of 10%, being $6.5M. Approximately $48M of the amount advanced by the New Lender was used to repay amounts owing by Acreage pursuant to the Prior Credit Agreement to the non-Canopy lender. As a result, the Prior Lender has been repaid in full. The net proceeds of the loan to Acreage totals approximately $8M after closing costs and expenses. The Amended and Restated Credit Agreement provides for an annual interest rate of 13.5% and matures on September 13, 2027. Interest in favour of the New Lender will be paid in cash. Interest in favour of Canopy is payable in cash or in kind at Acreage's option and will initially be payable in-kind. The Amended and Restated Credit Agreement also provides the New Lender with a board observer right.

08:48 EDT Vista Outdoor announces cash consideration for CSG deal raised to $28 per share - Vista Outdoor's board of directors issued the following statement: "We take seriously our duty to maximize value for stockholders. In our continued efforts to maximize stockholder value and in response to stockholder feedback, we have been conducting a thorough process with financial and legal advisors to evaluate all strategic alternatives for our businesses. We are pleased to report that the Board's process has yielded significant value for our stockholders. After extensive diligence, CSG has agreed to make a significant investment in Revelyst which delivers increased cash consideration to stockholders. On September 12, the Company entered into an amendment to the merger agreement with Czechoslovak Group a.s. ("CSG") in which CSG has agreed to purchase shares representing 7.5% of standalone Revelyst for $150 million (the "Revised CSG Transaction") at a price of ~$31 per Revelyst share, valuing Revelyst at $2.0 billion. Vista Outdoor notes that the Company's GEAR Up transformation program is delivering value in line with prior guidance. Revelyst continues to gain market share in key categories and is on track to double Adjusted EBITDA sequentially for the quarter and for the full year. The $150 million of cash payable by CSG for the purchase of Revelyst shares plus additional cash from Vista Outdoor's balance sheet will be returned to Vista Outdoor stockholders, increasing the cash consideration payable in the Revised CSG Transaction by $4 per share to $28 per share. At the closing of the Revised CSG Transaction, Vista Outdoor stockholders will receive $28 in cash per share and one share of Revelyst common stock for each share of Vista Outdoor common stock. Following the closing of the CSG Transaction, Revelyst plans to establish an initial $50 million share repurchase program. The MNC Revised Proposal significantly undervalues The Kinetic Group and Revelyst compared to the Revised CSG Transaction. On September 6, we received a revised proposal from MNC to acquire the Company for $43 in cash per share (the "MNC Revised Proposal"). Documentation delivered to the Board in connection with the MNC Revised Proposal implies a value of ~$1.9 billion for The Kinetic Group and ~$1.2 billion for Revelyst. In comparison, the Revised CSG Transaction represents a value of $2.15 billion for The Kinetic Group and an investment in Revelyst at a value of $2.0 billion. We have engaged extensively with MNC, accommodated MNC's diligence requests, and provided access to management. MNC has publicly confirmed that it completed its diligence. The Company notes that the MNC Revised Proposal does not represent an increase in enterprise value compared to MNC's prior proposal when considering Vista Outdoor's cash generated and lower net debt; however, we will continue to constructively engage with MNC and urge MNC to deliver its best and final proposal as soon as possible. Gates Capital is a conflicted party. The Board recently learned that the Company's second largest stockholder, Gates Capital Management Inc. ("Gates Capital"), is included in MNC's equity consortium. Given its involvement with MNC, Gates Capital's public expression in favor of MNC's proposal reflects a bias and conflict of interest. Consequently, Gates Capital's interests are not aligned with those of other Vista Outdoor stockholders. We urge stockholders to make their own informed decision based on the valuation differential between the Revised CSG Transaction and the MNC Revised Proposal. The Board is, and has always been, committed to maximizing value for all Vista Outdoor stockholders and remains open to opportunities that achieve this goal. The Board continues to recommend Vista Outdoor stockholders vote in favor of the proposal to adopt the merger agreement with CSG at the special meeting of stockholders (the "Special Meeting"), which will be held at 9:00 am (Central Time) on September 27, 2024. Morgan Stanley & Co. LLC is acting as sole financial adviser to Vista Outdoor and Cravath, Swaine & Moore LLP is acting as legal adviser to Vista Outdoor. Moelis & Company LLC is acting as sole financial adviser to the independent directors of Vista Outdoor and Gibson, Dunn & Crutcher LLP is acting as legal adviser to the independent directors of Vista Outdoor."

08:38 EDT Momentus selected by DARPA as member of BRIDGES consortium - Momentus has been selected by the Defense Advanced Research Projects Agency, or DARPA, Strategic Technology Office to become a member of the Bringing Classified Innovation to Defense and Government Systems, or BRIDGES, consortium. As part of the consortium, Momentus will be sponsored for a facility clearance, enabling the company to engage directly with Department of Defense, or DoD, customers at classified levels. Momentus' selection is based on their innovative technologies and capabilities that support the DoD's Space Superiority mission.

08:35 EDT Mill City Ventures III advances $1.15M to senior care provider - Mill City Ventures III announced its funding of a $1.15M short-term loan in facilitation of two senior care development projects.

08:32 EDT Ascendis Pharma to present first results on PROC cohort in Phase 1/2 trial - Ascendis Pharma A/S announced initial data showing signs of clinical activity in heavily pre-treated patients with platinum-resistant ovarian cancer, PROC, treated with TransCon IL-2 beta/gamma in combination with chemotherapy in its ongoing Phase 1/2 IL-Believe Trial of TransCon IL-2 beta/gamma. First results will be shared in Poster 762P at ESMO 2024, the annual meeting of the European Society of Medical Oncology being held in Barcelona from September 13-17, 2024. Of the 18 patients included in the initial data, 14 were efficacy evaluable patients who had 1 or more post-baseline tumor assessment, plus an additional 4 who discontinued treatment before the first post-baseline tumor assessment due to disease progression or death. Anti-tumor clinical responses were observed in 29% of the efficacy evaluable patients including patients whose disease had previously progressed on Elahere, suggesting clinical activity in heavily pre-treated patients.

08:17 EDT Gorilla announces share buyback of up to $6M - The company said, "Gorilla Technology Group is thrilled to announce an ambitious and strategic share buyback program, aimed at addressing what we believe to be a significant undervaluation of our shares. This initiative comes in response to the sharp decline in the Company's market cap from approximately $650M to $35M, in spite of our strong business performance. The share buyback will help realign Gorilla's stock price with our assessment of its intrinsic value and support our long-term strategic objectives." The Board of Directors has authorised the repurchase of up to $6 million worth of shares under this buyback programme. Under this program, Gorilla has entered into several privately negotiated transactions with existing shareholders to repurchase over 1.1 million of its ordinary shares, which transactions are expected to close over the next five business days. The Company will continue to opportunistically pursue additional share repurchases so long as this undervaluation persists.

08:10 EDT OS Therapies announces development of two ADC therapeutic candidate - OS Therapies announced the development and in vitro concept data for two novel ADC therapeutic candidates leveraging the company's proprietary SiLinker technology. The company has completed target engagement tests for both therapeutic candidates and confirmed their therapeutic potential. These new constructs will target Breast, Lung and Gastric Cancer; and Ovarian, Fallopian Tube and Primary Peritoneal Cancer, respectively. The company is advancing its tADC platform through successive product development de-risking milestones and intends to out-license certain therapeutic candidates and components that are strategic to potential partners' pipelines - particularly the ph-sensitive SiLinker. The company's first tADC asset OST-tADC-FRa-H has achieved proof of concept in animal models of ovarian cancer. With the additional two constructs now added to the pipeline, the company is positioning itself to become a provider of intellectual property for new therapeutic product development to partners. All while continuing to focus its internal resources on bringing to market the OST-HER2 off-the-shelf immunotherapy cancer vaccine platform for canines with osteosarcoma, and for humans with osteosarcoma and other HER2 positive cancers such as breast cancer and colorectal cancer.

08:06 EDT Iveda Solutions announces 1-for-8 reverse stock split - Iveda Solutions announced that it has approved a 1-for-8 reverse stock split of the outstanding and authorized shares of its common stock and corresponding adjustment to the publicly traded common stock purchase warrants. Pursuant to the reverse stock split, each eight shares of the company's outstanding common stock, $0.00001 par value per share, will be automatically combined and converted into one outstanding share of common stock. In addition, the current publicly traded common stock purchase warrants will be proportionately adjusted under the current terms of the warrant agreement so that each 8 warrants will be entitled to acquire one share of common stock at a revised purchase price per share of $34.00. The split will also reduce the number of the company's authorized common stock from 37,500,000 shares to 4,687,500 shares.

08:04 EDT Paramount Group suspends quarterly dividend - Paramount Group announced that its board of directors suspended the company's regular quarterly dividend that would have otherwise been payable on October 15. During 2024, Paramount paid three regular quarterly dividends aggregating 10.5c per share of common stock, which approximates 100% of its estimated 2024 taxable income.

08:04 EDT PodcastOne enters multi-year agreement for rights to Fools Coverage - PodcastOne (PODC), a subsidiary of LiveOne ( LVO), announced it has entered into a multi-year agreement for the exclusives sales and distribution rights to Fool Coverage with Manny MUA and Laura Lee. The Millennial and Gen Z favored influencer beauty gurus Manny and Laura Lee bring their top reviewed pop culture comedy podcast to PodcastOne for weekly episodes starting September 12, 2024.

08:03 EDT CSL, Arcturus Therapeutics announce Japan MHLW approval for Kostaive - CSL (CSLLY) and Arcturus Therapeutics (ARCT) announced that Japan's Ministry of Health, Labor and Welfare, or MHLW, granted approval and authorization for their updated self-amplifying mRNA COVID-19 vaccine, Kostaive. The updated vaccine is targeted to protect against the JN.1 lineage of Omicron subvariants for adults 18 years of age and older. CSL's exclusive partner in Japan, Meiji Seika Pharma, will begin distributing the updated vaccine in time for the October COVID-19 vaccination campaign, marking the world's first commercially available sa-mRNA COVID-19 vaccine for adults 18 and older. In May, a Japanese health ministry panel recommended that COVID-19 vaccines be updated to target the JN.1 lineage of Omicron subvariants for the 2024/2025 national immunization program. This aligns with recent recommendations from the World Health Organization.

08:03 EDT AFC Gamma announces first post-spin quarterly dividend of 33c per share - AFC Gamma announced its dividend for the quarter ending September 30, 2024. The Board of Directors of AFC declared a quarterly dividend of 33c for the quarter ending September 30, 2024 per outstanding share of common stock, payable on October 15, 2024 to the common stockholders of record on September 30, 2024.

08:02 EDT DZS announces CFO departure - DZS announced that Chief Financial Officer, CFO, Misty Kawecki will step down at the end of September following the successful completion of the company's financial restatement. Brian Chesnut has been named the interim Chief Financial Officer.

07:49 EDT Dundee Precious Metals provides Coka Rakita project update - Dundee Precious Metals provided an update on its Coka Rakita project, where the pre-feasibility is advancing on track for completion in the first quarter of 2025. The Company also reported new assay results from the recently completed PFS infill drilling program. Highlights: Pre-feasibility study on track: Continue to target completion of PFS the first quarter of 2025. Completion of the PFS infill drilling program: Results continue to confirm the continuity of a core zone of high-grade mineralization with the Mineral Resource outline. Highlights include: RIDD055 - 74 metres at 27.3 g/t Au, from 426 metres downhole, including 37 metres at 47.44 g/t Au and 0.11% Cu from 460 metres downhole. RIDD057 - 83 metres at 3.90 g/t Au and 0.24% Cu from 385 metres. RIDD060 - 71 metres at 3.39 g/t Au from 414 metres, including 7 metres at 10.71 g/t Au from 473 metres downhole. RIDD069 - 67 metres at 10.61 g/t Au and 0.23% Cu, from 387 metres. RIDD078A - 42 metres at 11.13 g/t Au and 0.18 % Cu from 263 metres. "We continue to unlock Coka Rakita's potential to add production growth and strong margins to our portfolio, with first production targeted for 2028," said David Rae, President and CEO. "As we accelerate the project through our development pipeline, we are progressing the PFS, which remains on track for Q1 2025, and advancing permitting activities to support start-up of construction in 2026. We have the financial and technical resources to advance this high-quality growth project and continue our exploration programs to further define the significant potential of Coka Rakita and the surrounding licences."

07:34 EDT Elanco provides update on relationship with TriRx - Elanco Animal Health provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd. TriRx entered into trading administration, a formal insolvency process in the United Kingdom designed to help companies facing severe financial challenges regain stability. Administrators from FTI Consulting LLP have been appointed. Elanco has a long-term supply agreement with TriRx to manufacture select farm animal products at the Speke site. Elanco is working constructively with the Administrators to support business continuity in the interim and explore possible options in the best interest of all stakeholders. In the short term, Elanco is working with the Administrators to underwrite the operational costs to ensure work in progress at the site continues and that employees will be paid during the interim. As a result of this engagement, Elanco expects minimal supply disruption in 2024. Elanco expects a reduction of approximately $5M-$10M of adjusted EBITDA in 2024 related to the TriRx situation. Despite this headwind, Elanco continues to expect to deliver its full year adjusted EBITDA guidance of $900M-$940M.

07:04 EDT Kaixin Auto announces Nasdaq allows temporary exception to regain compliance - Kaixin announced that it received a letter dated September 12, 2024 from the Nasdaq Hearings Panel), indicating that the Panel has determined to grant the Company a temporary exception to regain compliance with The Nasdaq Stock Market LLC's Listing Rule 5550(a)(2") by December 13, 2024. The Company is scheduled to hold an extraordinary general meeting on October 1, 2024 to obtain shareholders' approval for a reverse stock split. The Company aims to effectuate a reverse stock split by November 30, 2024, and to regain compliance with the Bid Price Rule by December 13, 2024.

07:02 EDT Xortx Therapeutics announces results of Annual, Special Meeting - XORTX Therapeutics announced the results of its annual and special meeting of shareholders held Thursday, September 12, 2024. A total of 889,288 common shares of the Company were represented at the Meeting, representing approximately 31% of the total number of common shares of the Company issued and outstanding. All matters presented for approval at the Meeting were duly authorized and approved including election of all seven management nominees to the board of directors of the Company, the appointment of Smythe LLP as auditors of the Company for the ensuing year and authorization of the directors to fix their remuneration, and re-approval of the stock option plan

06:52 EDT ANI Pharmaceuticals launches Promethazine Hydrochloride - ANI Pharmaceuticals announced the launch of Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution, 6.25 mg/15 mg per 5 mL. U.S. annual sales for Promethazine Hydrochloride and Dextromethorphan Hydrobromide Oral Solution total approximately $42.6M, based on July 2024 moving annual total IQVIA data.

06:17 EDT GSK announces CDE of NMPA in China granted BTD for Blenrep - GSK announced that the Center for Drug Evaluation, CDE, of the National Medical Products Administration, NMPA, in China has granted Breakthrough Therapy Designation, BTD, for Blenrep combined with bortezomib plus dexamethason, BorDex, for the treatment of relapsed or refractory multiple myeloma. NMPA BTD is intended to expedite the development of therapies for serious and life-threatening diseases for which there are no existing treatments or where initial evidence has shown an improvement in patient outcomes over available treatment options. BTD was granted based on the interim results of the phase III head-to-head DREAMM-7 trial, which met its primary endpoint, showing statistically significant and clinically meaningful improvements in progression-free survival for belantamab mafodotin combined with BorDex compared to daratumumab plus BorDex in relapsed or refractory multiple myeloma.

06:07 EDT Nuvve Holding announces 1-for-10 reverse stock split - Nuvve Holding announced that it will effect a 1-for-10 reverse stock split of its common stock, to be effective as of 5:00 p.m. Eastern Time on Monday, September 16. Nuvve's common stock will begin trading on a split-adjusted basis commencing upon market open on Tuesday, September 17.

06:05 EDT Precision Drilling renews normal course issuer bid - Precision Drilling announced that the Toronto Stock Exchange has approved its intention to implement a normal course issuer bid for a portion of its common shares. Precision believes the NCIB continues to represent another tool for the company to enhance the value of its underlying shares. Pursuant to the renewed NCIB, the company has been authorized by the TSX to acquire up to a maximum of 1,359,108 Common Shares, or approximately 10% of the public float as of September 5, 2024, for cancellation. As of September 5, 2024, Precision had 14,107,373 Common Shares issued and outstanding and a public float of 13,591,089 Common Shares. Purchases under the NCIB may commence on September 19, 2024 and will terminate no later than September 18, 2025, or such earlier time as the company completes its purchases pursuant to the NCIB or provides notice of termination.

06:01 EDT Laureate Education announces $100M share repurchase plan - Laureate Education announced that its board of directors has approved a new stock repurchase program to acquire up to $100M of the company's common stock. The Company intends to finance the repurchases with free cash flow, excess cash and liquidity on-hand, including available capacity under its Revolving Credit Facility. The company has completed the $100M repurchase program that had previously been announced in February 2024. After giving effect to this new authorization, the company will have returned nearly $3B of capital to shareholders since the beginning of 2019 through a combination of share repurchases, cash distributions and cash dividends.

05:37 EDT Flutter acquires 56% stake in Brazil's NSX Group for $350M - Flutter Entertainment announced the acquisition of an initial 56% stake in NSX Group, a Brazilian operator of the Betnacional brand for cash consideration of approximately $350M. "The transaction fully aligns with Flutter's strategy to invest in leadership positions in international markets, securing a podium position for Flutter on completion in the regulating and fast-growing Brazilian market," the company said in a statement. On a standalone basis, NSX is expected to generate revenue of approximately $256M and adjusted EBITDA of approximately $34M in 2024. Under the transaction agreement, on completion, Flutter will pay cash consideration of approximately $350M and contribute its existing Betfair Brazil business, in return for a 56% stake in the newly combined Flutter Brazil business. In addition, a mechanism has been put in place to enable Flutter to increase its shareholding through reciprocal put/call arrangements in year five and year ten following the completion date. The company said revenue synergies will be achieved by providing NSX access to Flutter proprietary pricing and risk management capabilities "to deliver a differentiated sportsbook product offering."

05:20 EDT Boeing factory workers strike after rejecting contract proposal - The International Association of Machinists and Aerospace Workers released a statement on IAM District 751 and W24's rejection of a tentative agreement with the Boeing: "We are incredibly proud of the hard work and dedication shown by the negotiating teams from District 751 and W24 and the unwavering solidarity of our membership. Their tireless efforts have been on display throughout this entire process. Now, they will regroup and begin planning the next steps on securing an agreement that our membership can approve. We will make every resource available for our District 751 and W24 members during this challenging time. IAM members from across North America stand in solidarity with our members in the Pacific Northwest and California. Our goal is to get a strong contract that meets the needs of our members." Shares of Boeing are down 4% to $156.46 in premarket trading. Reference Link

05:08 EDT Uxin enters MOU with Pintu Information Technology for proposed investment - Uxin announced that it has entered into a memorandum of understanding, or MOU, with Pintu Information Technology, an indirect wholly-owned subsidiary of Dida, with respect to a proposed investment in the company by the investor. Pursuant to the MOU, the investor intends to subscribe for 1,543,845,204 Class A ordinary shares of the company for an aggregate subscription amount of $7.5M, based on a subscription price of US$0.004858 per share. The proposed investment is subject to the parties' execution of definitive agreements and closing conditions to be stipulated therein. In connection with the proposed investment, the investor and the Youxin Industrial Investment have entered into a loan agreement pursuant to which the Investor agrees to extend a loan in a principal amount of RMB equivalent of $7.5M to Youxin Anhui. Youxin Anhui is a wholly-owned subsidiary of the company.